Archit Organosys (Small Cap) Share Target 2026, 2027 To 2035
|
Archit Organosys Limited |
|||
|
Price: ₹52.72 (0.4%) | ||
| 52 Week Low: ₹34.00 52 Week High: ₹57.80 |
|||
| Market Capital: 111.24 Crore (Small-cap) | |||
| -> | |||
Show Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Archit Organosys Share Price Target For 2026
- 1.1.1: Archit Organosys Share Price Target Table For 2026
- 1.1.2: Short-Term Technical Outlook
- 1.2: Archit Organosys Share Price Target For 2027
- 1.2.1: Archit Organosys Share Price Target Table For 2027
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Archit Organosys Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
- 3: Archit Organosys Financial Performance
- 3.0.1: Is Archit Organosys A Good Buy For Long Term?
Archit Organosys, a Small Cap company has delivered 16.4% returns in 1-year with 26.8% profit margin.
To predict the Archit Organosys's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Archit Organosys Share Price Target For 2026
The line chart displays the monthly closing prices of Archit Organosys with a black line. The green line shows three potential target prices for 2026, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Archit Organosys shares in 2026, see the table below.
Archit Organosys Share Price Target Table For 2026
| Level | Value | Analysis |
|---|---|---|
| 2026 Target 3 | 58.73 (+11.39%) | Volatility: ATR T1 |
| 2026 Target 2 | 55.24 (+4.77%) | Trend: Supertrend Resistance |
| 2026 Target 1 | 55.06 (+4.43%) | Volatility: BB Upper |
| Current Price | 52.72 | Archit Organosys's share price as of 15 Jun 2026 |
| Stop Loss 1 | 52.34 (-0.73%) | Trend: EMA9 |
| Stop Loss 2 | 49.34 (-6.42%) | Trend: SMA50 |
| Stop Loss 3 | 48.71 (-7.61%) | 38.20% Weekly Fib Retrace |
Short-Term Technical Outlook
Current Technical Position: Archit Organosys is showing bullish momentum with price above both 25-day and 50-day moving averages.
Key Technical Level: The 50-day moving average at ₹49.34 serves as the nearest technical reference point.
Historical Returns: 3-month: +44.2% | 6-month: +25.49% | 1-year: +16.35%
Archit Organosys Share Price Target For 2027
The line chart displays the monthly closing prices of Archit Organosys with a black line. The green line shows three potential target prices for 2027, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Archit Organosys shares in 2027, see the table below.
Archit Organosys Share Price Target Table For 2027
| Level | Value | Analysis |
|---|---|---|
| 2027 Target 3 | 58.73 (+11.39%) | Volatility: ATR T1 |
| 2027 Target 2 | 55.24 (+4.77%) | Trend: Supertrend Resistance |
| 2027 Target 1 | 55.06 (+4.43%) | Volatility: BB Upper |
| Current Price | 52.72 | Archit Organosys's share price as of 15 Jun 2026 |
| Stop Loss 1 | 52.34 (-0.73%) | Trend: EMA9 |
| Stop Loss 2 | 49.34 (-6.42%) | Trend: SMA50 |
| Stop Loss 3 | 48.71 (-7.61%) | 38.20% Weekly Fib Retrace |
Long-Term Technical Outlook
52-Week Range Analysis: Archit Organosys is currently trading near its 52-week high of ₹57.8, showing strong yearly momentum.
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +16.35% | 3-year: -18.07% | 5-year: +12.56%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Archit Organosys Share Price Target Chart and Table From 2026, 2027, 2028 to 2035
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹52.72 | ||
| 2026 | ₹67.98 | +28.945371775417% | ₹69.00 |
| 2027 | ₹84.51 | +24.315975286849% | ₹85.78 |
| 2028 | ₹112.19 | +32.753520293456% | ₹113.87 |
| 2029 | ₹141.84 | +26.428380426063% | ₹143.97 |
| 2030 | ₹188.53 | +32.917371686407% | ₹191.36 |
| 2031 | ₹225.95 | +19.848300005304% | ₹229.34 |
| 2032 | ₹272.17 | +20.455853064837% | ₹276.25 |
| 2033 | ₹349.14 | +28.280119043245% | ₹354.38 |
| 2034 | ₹381.45 | +9.2541673827118% | ₹387.17 |
| 2035 | ₹429.32 | +12.549482238826% | ₹435.76 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Archit Organosys Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 67.62 Crore | Market valuation of Archit Organosys's shares. |
| Revenue (TTM) | 113.19 Crore | Total revenue generated by Archit Organosys over the past twelve months. |
| Net Income (TTM) | +3.27 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | 6.09% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | 26.83% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
-12.86% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.41 | Company's total debt divided by total shareholder equity. |
| Total Debt | 26.44 Crore | Sum of Archit Organosys's current & long-term financial obligations. |
Is Archit Organosys A Good Buy For Long Term?
Archit Organosys, a small-cap stock with a market capitalization of ₹67.62 crore, presents a mixed picture for long-term investment. While its ₹113.19 crore revenue (TTM) and ₹3.27 crore net profit are positive, a significant debt of ₹26.44 crore (Q1 2024-25) raises concerns. Negative returns over the past year (-19.79% to -20.96%) and a recent quarterly revenue drop of -12.86% are also worrying. Although past 3-year returns are strong (104.89%), the current financial indicators suggest it's not a good buy for long-term investors at this time. Further analysis is recommended.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.




